Integer Holdings Corp stock (US45826J1051): steady trading after recent Q1 update

Integer Holdings Corp shares traded steadily in the United States at the end of May following the company’s recent first-quarter 2026 earnings release, keeping investor focus on the medical technology group’s growth outlook and balance between cardiovascular, neuromodulation and vascular product demand.

Integer Holdings Corp shares on the New York Stock Exchange traded broadly in line with recent levels at the end of May, following the United States-based medical device manufacturer’s publication of its latest quarterly results earlier in May 2026, which kept attention on demand for its cardiovascular and neuromodulation components and contract manufacturing services, according to data from NYSE trading screens as of 05/31/2026.

The stock, listed under the ticker ITGR in the United States, reflected investor reactions to the company’s first-quarter 2026 earnings update released in early May, where management detailed revenue trends across cardiac and vascular, neuromodulation and advanced surgical segments alongside comments on hospital procedure volumes and customer inventory patterns, according to the company’s investor relations materials.

For investors in the United States, the New York listing and reporting in USD remain the primary reference points for Integer Holdings Corp, with the shares continuing to trade on the NYSE and to be governed by U.S. Securities and Exchange Commission disclosure standards as of late May 2026, based on exchange disclosures and company filings.

Some international investors also access Integer Holdings Corp shares via secondary trading venues in Europe such as Tradegate or Frankfurt in Germany, where the stock is quoted in EUR and offers an additional point of access to the U.S.-listed equity for cross-border portfolios, according to German trading venue information as of 05/31/2026.

As of: 01/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: ITGR
• Sector/industry: Medical technology, OEM medical device manufacturing
• Headquarters/country: Plano, United States
• Core markets: North America, Europe and selected Asia-Pacific healthcare markets
• Key revenue drivers: Cardiovascular and neuromodulation components, cardiac and vascular access products, and contract manufacturing for medical device companies
• Home exchange/listing venue: New York Stock Exchange (ITGR)
• Trading currency: USD

Integer Holdings Corp: core business model

Integer Holdings Corp focuses on supplying specialized components and finished devices to larger medical technology companies, generating most of its revenue from cardiovascular, neuromodulation and advanced surgical solutions as well as contract manufacturing services for original equipment manufacturers.

What banks and research houses say about Integer Holdings Corp

Sell-side coverage for Integer Holdings Corp in the United States centers on its positioning as a supplier to leading medical device manufacturers, with analysts typically examining trends in procedure volumes, hospital capital spending and OEM product launches when evaluating the stock, according to recent equity research reports from major U.S. investment banks and regional healthcare-focused brokers published in 2026.

Across this research community, key themes include Integer Holdings Corp’s exposure to cardiovascular therapies, including cardiac rhythm management and electrophysiology, as well as its participation in neuromodulation and vascular access markets, where analysts track new product introductions by the company’s OEM customers and discuss how shifts in demand across these therapeutic areas may influence Integer’s medium-term growth profile and margin trajectory.

Conclusion

Integer Holdings Corp’s share price in the United States has been trading stably in late May 2026 following the company’s early May first-quarter earnings release, keeping attention on its exposure to cardiovascular and neuromodulation demand trends rather than on sharp short-term price swings.

Analyst commentary continues to emphasize the company’s role as a supplier to leading medical technology manufacturers and the importance of procedure volumes, OEM product cycles and hospital budgets for the company’s medium-term revenue and margin development, which remain at the center of the investment debate around the stock.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.